Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab. [PDF]
Tsuzuki Wada T +12 more
europepmc +1 more source
Serum Soluble Interleukin-2 Receptor as a Potential Marker for Assessing Disease Activity in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease. [PDF]
Ozaki T +8 more
europepmc +1 more source
Emerging treatments in Castleman disease – a critical appraisal of siltuximab [PDF]
core +2 more sources
Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib. [PDF]
Fukui S +13 more
europepmc +1 more source
Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease [PDF]
core +2 more sources
Successful Treatment of Idiopathic Multicentric Castleman Disease With Rash as the Initial Symptom Using a Rituximab-Based Regimen. [PDF]
Zhu L +7 more
europepmc +1 more source
Plasma Cell-rich Nephritis with a Systemic Polyclonal Lymphoproliferative Disorder, Mimicking Idiopathic Multicentric Castleman Disease, Systemic Lupus Erythematosus, and IgG4-related Disease. [PDF]
Hebisawa Y +4 more
europepmc +1 more source
Idiopathic Multicentric Castleman Disease Diagnosed after Lower Extremity Venous Thrombosis Mimicking Immunoglobulin G4-related Disease. [PDF]
Suzuki E +7 more
europepmc +1 more source
Unraveling the Complexities of Idiopathic Multicentric Castleman Disease and Its Multi-systemic Associations: A Case Report. [PDF]
Palvia AR +4 more
europepmc +1 more source

